Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from a Phase III trial, highlighting the efficacy of its anticoagulant Xarelto (rivaroxaban) in reducing the risk of clinically significant bleeding (CSB) and net adverse clinical events (NACE) or rehospitalization in adult patients with nonvalvular atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI). The trial data, which compared Xarelto to warfarin, showed a notable decrease in CSB rates among elderly individuals from 31.4% to 21.3%, and among non-elderly participants from 24.6% to 15.3%.
The reduced risk of CSB associated with Xarelto intake corresponded to a diminished risk of NACE or rehospitalization by 23% in elderly patients and by 31% in non-elderly patients. Furthermore, the trial observed significant decreases in both major and minor bleeding rates across both age groups. Major bleeding rates dropped from 5.2% to 3.7% in the elderly and from 2.5% to 1.1% in non-elderly individuals. Minor bleeding rates also saw a decline, from 3.8% to 1.4% in the elderly and from 1.4% to 1.0% in non-elderly participants.
These findings underscore Xarelto’s potential as a safer alternative to warfarin for managing blood thinning treatment in high-risk AF patients, offering a promising outlook for reducing bleeding complications and improving patient outcomes following PCI.- Flcube.com
